A Phase III, Open Label,Extension Trial of ECU-MG-301 to evaluate the Safety and Efficacy of Eculizumab in subjects with Refractory Generalized Myasthenia Gravis
Clinical Trial Grant
Administered By
Neurology, Neuromuscular Disease
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
October 1, 2014
End Date
September 24, 2019
Administered By
Neurology, Neuromuscular Disease
Awarded By
Alexion Pharmaceuticals, Inc.
Start Date
October 1, 2014
End Date
September 24, 2019